Physician

Charles Atkinson Zollinger, M.D.

According to 2025 Medicare claims, Charles Zollinger, M.D. (NPI: 1619923133) practices neurology in the Canton-Massillon, OH market, with the plurality of this provider's patient population coming from Stark, OH. This provider's primary affiliated billing organization is NEUROCARE CENTER INC (NPI: 1689769572; TIN: 341257807) and primary practice location at 44718-2531. Zollinger is affiliated with the IHC Quality Partners, LLC (ACO ID: A2833), participating under the MSSP model.

Zollinger's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 751 traditional Medicare patients, billed 10,737 HCPCS/CPT codes, and received $147,194 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 4,170 prescription claims across 760 beneficiaries totaling $1,247,142 in drug costs, led by Kesimpta Pen (Ofatumumab). 2021 DME data shows 11 claims. Open Payments data shows 24 records totaling $415. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $419 to $22,328.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	663	1,119	$82,573
2016	771	1,468	$94,258
2017	718	1,517	$93,905
2018	771	2,482	$95,981
2019	714	2,819	$92,911
2020	600	2,660	$76,954
2021	690	1,187	$97,070
2022	742	1,266	$93,239
2023	690	2,043	$91,172
2024	751	10,737	$147,194

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	410	2,798	$1,649,695
2016	405	2,837	$1,745,397
2017	469	3,052	$1,546,073
2018	501	3,527	$1,101,805
2019	482	3,206	$798,045
2020	497	3,290	$939,687
2021	565	3,740	$1,017,582
2022	526	3,513	$934,582
2023	562	3,234	$1,107,968
2024	760	4,170	$1,247,142

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$84
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	11	$1,609
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	166	166	$116
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	471	655	$87
95886	Needle measurement of electrical activity in arm or leg muscles, complete study	33	62	$74
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	174	195	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	566	813	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Kesimpta Pen	Ofatumumab	23	688	$210,610
Aubagio	Teriflunomide	12	360	$110,351
Tysabri	Natalizumab	13	364	$106,251
Avonex Pen (4 Pack)	Interferon Beta-1a	13	364	$105,956
Dimethyl Fumarate	Dimethyl Fumarate	24	840	$88,031

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	24	$415	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Charles Atkinson Zollinger, M.D.?

Tedicare shows public-source Medicare data for Charles Atkinson Zollinger, M.D. (NPI 1619923133), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles Atkinson Zollinger, M.D. have ACO affiliation data?

Charles Atkinson Zollinger, M.D. is shown with ACO affiliation data for IHC Quality Partners, LLC (MSSP, ACO ID A2833).

What billing organization is linked to Charles Atkinson Zollinger, M.D.?

Charles Atkinson Zollinger, M.D. is linked to NEUROCARE CENTER INC (billing NPI 1689769572) in the available physician profile data.

Does Charles Atkinson Zollinger, M.D. have Open Payments data?

Charles Atkinson Zollinger, M.D. has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.